Breast Biopsy Supply Chain Fragility: Three Mitigation Strategies After the 2026 Hologic Needle Recall

The Jan 2026 Hologic Brevera 9-gauge needle recall—triggering an FDA shortage—laid bare single-source dependency in vacuum-assisted biopsy. This JACR analysis argues stockpiling, vendor diversification, and procurement standardization are each necessary but none sufficient alone…

• Design: Expert perspective/operational analysis; no patient cohort or comparative statistics — no effect sizes, CIs, or p-values are reported.
• The January 2026 Hologic Brevera 9-gauge needle recall and subsequent FDA shortage designation serve as the index event; the piece is descriptive and prescriptive rather than empirical.
• Key limitation: no quantitative outcomes data or external validation of the proposed framework; recommendations are consensus-level and may not generalize across all practice sizes or resource settings. Community sites are explicitly flagged as underserved by enterprise-scale redistribution plans.

RadPigeon summaries are original and for information only. They are not clinical advice.